Jazz Pharmaceuticals plc (JAZZ) fair value analysis

Nasdaq · Updated 2026-09-07

Jazz Pharmaceuticals plc is a biopharmaceutical company that develops, manufactures, and commercializes medicines for patients with serious conditions across various therapeutic areas including neuroscience, oncology, and other specialized areas. The company operates globally with research, development, and commercial operations across multiple countries including the United States, Europe, and other international markets.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, JAZZ is trading at within about 10% of estimated fair value.

JAZZ currently ranks #81 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $251.58
Sector: Healthcare
12-month range: $136.90–$251.58

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for JAZZ

Our model validated 17 trailing price-to-earnings windows for JAZZ, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $136.90–$251.58.
The 14-day relative strength index sits at a neutral 41.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for JAZZ
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent JAZZ news

TickrTrends' derived news-sentiment signal for JAZZ is currently leaning positive, computed from recent coverage.

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone? (insidermonkey.com, 2026-09-04)
TickrTrends take: Jazz Pharmaceuticals' Ziihera demonstrated superior overall survival compared to trastuzumab, a widely used HER2-targeted therapy, which could expand its addressable market if regulatory approval follows. Given the company's Fairly valued status, investors should monitor whether this clinical data translates into meaningful revenue contribution and market share gains in the competitive HER2-positive treatment landscape. The commercial success of Ziihera as a first-line option would be a key factor in justifying or adjusting the current valuation relative to peer performance in the oncology space.
JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment (gurufocus.com, 2026-08-31)
TickrTrends take: JAZZ is currently assessed as fairly valued by TickrTrends despite the recent positive trial data mentioned in the headline, which suggests the market may have already incorporated these results into the stock price. The divergence between GF Value's assessment and TickrTrends' fairly valued rating indicates different methodologies are reaching different conclusions about whether recent developments have moved the stock beyond its intrinsic value. Investors focused on valuation metrics should monitor whether upcoming earnings reports or additional clinical developments shift this equilibrium in either direction.
JAZZ Looks 64.2% Overvalued on GF Value™ Amid $1.1B Note Offering (gurufocus.com, 2026-08-27)
TickrTrends take: Jazz Pharmaceuticals operates in the Healthcare sector where valuation assessments can shift significantly based on capital structure changes. The company's announcement of a 1 billion dollar note offering comes at a time when TickrTrends assigns it a Fairly valued rating, creating a potential divergence between different valuation methodologies that investors tracking the stock should monitor closely. A valuation-focused reader should observe whether the financing activity and its intended uses will influence how the company's fair value estimate evolves in coming quarters.

What people are saying

Follow the JAZZ conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — JAZZ's valuation assessment shifted this week as TickrTrends' DCF cross-check band moved from fairly valued to undervalued, while the stock maintains its position in the Healthcare sector. This change in the derived indicator suggests the company's intrinsic value may exceed its current market price based on discounted cash flow analysis. The overall current valuation verdict remains fairly valued.
2026-09-06 — JAZZ's momentum indicator declined this week, shifting from a grade of A to none, indicating a loss of upward price movement. The stock maintains a fairly valued assessment based on current valuation metrics. This change suggests reduced buying pressure compared to the previous week.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is JAZZ stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), JAZZ is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is JAZZ's TickrTrends verdict?

JAZZ's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does JAZZ compare to other Healthcare stocks?

JAZZ ranks #81 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is JAZZ overbought or oversold?

JAZZ's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

JAZZ vs ABBV · JAZZ vs ACHC · JAZZ vs BIIB · JAZZ vs BVS · JAZZ vs HCSG